PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced pulmonary hypertension via attenuating epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling in vivo and in vitro
PCSK9 plays a crucial role in the progression of PF-induced PH by regulating cell EMT and Wnt/β-catenin signaling. Targeting PCSK9 expression or activity could effectively control lung fibrosis and its PH complication.
Authors
- Xiaowan Wang (ORCID: https://orcid.org/0000-0001-9152-8908)
- Di Yin (ORCID: https://orcid.org/0000-0002-3272-9643)
- Qiang Guo (ORCID: https://orcid.org/0009-0001-0995-755X)
- Zetao Pan
- Jiancheng Lin (ORCID: https://orcid.org/0000-0003-4214-6107)
- Jiayan Sun
- Cunyang Huo
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
- The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fmed.2024.1509168
- Citations
- 4
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.68